Clinical Benefits of Following Therapy after Anti-HER2 Standard Therapy for HER2-positive, Unresectable and/or Metastatic Breast Cancer: a Retrospective Registry Study (KBCSG-TR 1917)
Not Applicable
- Conditions
- HER2-positive, unresectable and/or metastatic breast cancer
- Registration Number
- JPRN-UMIN000038296
- Lead Sponsor
- Kinki Breast Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 128
Inclusion Criteria
Not provided
Exclusion Criteria
1) Has received any investigational new drug or any approved drug without breast cancer indication in any clinical trial as the following therapy after T-DM1 treatment 2) Has declined to participate in this study before the database has been locked
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.rwPFS:Real world progression-free survival 2.TTF:Time to treatment failure 3.OS:Overall survival 4.ORR:Objective response rate 5.CBR:Clinical benefit rate
- Secondary Outcome Measures
Name Time Method